Three year study of adefovir dipivoxil (ADV) demonstrates sustained efficacy in presumed precore mutant chronic hepatitis B (CHB) patients in a long term safety and efficacy study (LTES) - Hadziyannis,S.J.; Tassopoulos,N.; Chang,T.T. (J Hepatol, 2004)